Small cell lung cancer can express CD34 antigen

Hiromichi Yamane, Katsuyuki Kiura, Masahiro Tabata, Akihiro Bessho, Tadashi Tsuchida, Kinya Motoda, Akio Hiraki, Hiroshi Ueoka, Mine Harada

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In humans CD34 is a valid and reliable marker for hematopoletic stem and progenitor cells. In general, solid tumors, with the exception of endothelial cancers, do not express CD34. Accordingly, immunological selection of CD34+ hematopoietic stem/progenitor cells can be used to remove CD34- malignant cells in the setting of autotransplantation. To rule out CD34 expression on tumor cells from small cell lung cancer (SCLC), eleven SCLC cell lines were analyzed by flow cytometry. Interestingy, two of these were positive for CD34 and their expression of full-length CD34 was further confirmed by reverse transcriptase and polymerase chain reaction (RT-PCR). This finding indicates that prior to subjecting SCLC patients to the above treatment modality, preparing CD34+ hematopoietic stem/progenitor cells from SCLC patients for autotransplantation, CD34 expression on their tumour cells should be screened using immunohistochemistry and/or flow cytometry.

Original languageEnglish
Pages (from-to)3627-3632
Number of pages6
JournalAnticancer Research
Volume17
Issue number5 A
Publication statusPublished - Sep 1997

Fingerprint

CD34 Antigens
Small Cell Lung Carcinoma
Hematopoietic Stem Cells
Autologous Transplantation
Neoplasms
Flow Cytometry
Stem Cells
Reverse Transcriptase Polymerase Chain Reaction
Immunohistochemistry
Cell Line

Keywords

  • CD34
  • Flow cytometry
  • RT-PCR
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamane, H., Kiura, K., Tabata, M., Bessho, A., Tsuchida, T., Motoda, K., ... Harada, M. (1997). Small cell lung cancer can express CD34 antigen. Anticancer Research, 17(5 A), 3627-3632.

Small cell lung cancer can express CD34 antigen. / Yamane, Hiromichi; Kiura, Katsuyuki; Tabata, Masahiro; Bessho, Akihiro; Tsuchida, Tadashi; Motoda, Kinya; Hiraki, Akio; Ueoka, Hiroshi; Harada, Mine.

In: Anticancer Research, Vol. 17, No. 5 A, 09.1997, p. 3627-3632.

Research output: Contribution to journalArticle

Yamane, H, Kiura, K, Tabata, M, Bessho, A, Tsuchida, T, Motoda, K, Hiraki, A, Ueoka, H & Harada, M 1997, 'Small cell lung cancer can express CD34 antigen', Anticancer Research, vol. 17, no. 5 A, pp. 3627-3632.
Yamane H, Kiura K, Tabata M, Bessho A, Tsuchida T, Motoda K et al. Small cell lung cancer can express CD34 antigen. Anticancer Research. 1997 Sep;17(5 A):3627-3632.
Yamane, Hiromichi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Bessho, Akihiro ; Tsuchida, Tadashi ; Motoda, Kinya ; Hiraki, Akio ; Ueoka, Hiroshi ; Harada, Mine. / Small cell lung cancer can express CD34 antigen. In: Anticancer Research. 1997 ; Vol. 17, No. 5 A. pp. 3627-3632.
@article{3223605298ee445aacb782eb6e28dd28,
title = "Small cell lung cancer can express CD34 antigen",
abstract = "In humans CD34 is a valid and reliable marker for hematopoletic stem and progenitor cells. In general, solid tumors, with the exception of endothelial cancers, do not express CD34. Accordingly, immunological selection of CD34+ hematopoietic stem/progenitor cells can be used to remove CD34- malignant cells in the setting of autotransplantation. To rule out CD34 expression on tumor cells from small cell lung cancer (SCLC), eleven SCLC cell lines were analyzed by flow cytometry. Interestingy, two of these were positive for CD34 and their expression of full-length CD34 was further confirmed by reverse transcriptase and polymerase chain reaction (RT-PCR). This finding indicates that prior to subjecting SCLC patients to the above treatment modality, preparing CD34+ hematopoietic stem/progenitor cells from SCLC patients for autotransplantation, CD34 expression on their tumour cells should be screened using immunohistochemistry and/or flow cytometry.",
keywords = "CD34, Flow cytometry, RT-PCR, Small cell lung cancer",
author = "Hiromichi Yamane and Katsuyuki Kiura and Masahiro Tabata and Akihiro Bessho and Tadashi Tsuchida and Kinya Motoda and Akio Hiraki and Hiroshi Ueoka and Mine Harada",
year = "1997",
month = "9",
language = "English",
volume = "17",
pages = "3627--3632",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Small cell lung cancer can express CD34 antigen

AU - Yamane, Hiromichi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Bessho, Akihiro

AU - Tsuchida, Tadashi

AU - Motoda, Kinya

AU - Hiraki, Akio

AU - Ueoka, Hiroshi

AU - Harada, Mine

PY - 1997/9

Y1 - 1997/9

N2 - In humans CD34 is a valid and reliable marker for hematopoletic stem and progenitor cells. In general, solid tumors, with the exception of endothelial cancers, do not express CD34. Accordingly, immunological selection of CD34+ hematopoietic stem/progenitor cells can be used to remove CD34- malignant cells in the setting of autotransplantation. To rule out CD34 expression on tumor cells from small cell lung cancer (SCLC), eleven SCLC cell lines were analyzed by flow cytometry. Interestingy, two of these were positive for CD34 and their expression of full-length CD34 was further confirmed by reverse transcriptase and polymerase chain reaction (RT-PCR). This finding indicates that prior to subjecting SCLC patients to the above treatment modality, preparing CD34+ hematopoietic stem/progenitor cells from SCLC patients for autotransplantation, CD34 expression on their tumour cells should be screened using immunohistochemistry and/or flow cytometry.

AB - In humans CD34 is a valid and reliable marker for hematopoletic stem and progenitor cells. In general, solid tumors, with the exception of endothelial cancers, do not express CD34. Accordingly, immunological selection of CD34+ hematopoietic stem/progenitor cells can be used to remove CD34- malignant cells in the setting of autotransplantation. To rule out CD34 expression on tumor cells from small cell lung cancer (SCLC), eleven SCLC cell lines were analyzed by flow cytometry. Interestingy, two of these were positive for CD34 and their expression of full-length CD34 was further confirmed by reverse transcriptase and polymerase chain reaction (RT-PCR). This finding indicates that prior to subjecting SCLC patients to the above treatment modality, preparing CD34+ hematopoietic stem/progenitor cells from SCLC patients for autotransplantation, CD34 expression on their tumour cells should be screened using immunohistochemistry and/or flow cytometry.

KW - CD34

KW - Flow cytometry

KW - RT-PCR

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0030828718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030828718&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 3627

EP - 3632

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -